{"id":"W1589654967","doi":"10.1056/nejmoa1409547","title":"Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":1621,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Ivacaftor; Medicine; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Placebo; Randomization; Internal medicine; Clinical endpoint; Gastroenterology; Randomized controlled trial; Urology; Surgery; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01897476457399061,"score_gpt":0.2954351084460771,"score_spread":0.2764603438720865,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}